Opendata, web and dolomites

EBiSC2 SIGNED

EBiSC2 – A sustainable European Bank for induced pluripotent Stem Cells

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "EBiSC2" data sheet

The following table provides information about the project.

Coordinator
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. 

Organization address
address: HANSASTRASSE 27C
city: MUNCHEN
postcode: 80686
website: www.fraunhofer.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 8˙872˙547 €
 EC max contribution 4˙599˙648 € (52%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2017-13-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2022-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. DE (MUNCHEN) coordinator 2˙463˙250.00
2    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) participant 999˙990.00
3    BIONEER A/S DK (HOERSHOLM) participant 374˙625.00
4    Department of Health UK (Leeds) participant 300˙208.00
5    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) participant 236˙575.00
6    ARTTIC FR (PARIS) participant 225˙000.00
7    BAYER AKTIENGESELLSCHAFT DE (Leverkusen) participant 0.00
8    Eli Lilly and Company Limited UK (Basingstoke) participant 0.00
9    FUJIFILM CELLULAR DYNAMICS INC US (MADISON WI) participant 0.00
10    H. LUNDBECK AS DK (VALBY) participant 0.00
11    INSTITUT DE RECHERCHES SERVIER FR (SURESNES) participant 0.00
12    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
13    NOVO NORDISK A/S DK (BAGSVAERD) participant 0.00
14    PFIZER LIMITED UK (SANDWICH) participant 0.00
15    TAKEDA DEVELOPMENT CENTRE EUROPE LTD UK (LONDON) participant 0.00
16    UCB BIOPHARMA SRL BE (BRUXELLES) participant 0.00

Map

 Project objective

EBiSC2 builds on the achievements of the European Bank for iPSCs (EBiSC1) in centralising existing capacities across Europe in a unique banking and distribution infrastructure for research use in response to the increasing demand for human induced pluripotent stem cells (iPSC). Significant progress towards this aim has been made by EBiSC1; further resources, however, are required to ensure self-sustainability. Key partners of EBiSC1 who have delivered major assets of the current bank, join efforts to establish EBiSC2 as self-sustainable, central bank. Based on a gap analysis of the EBiSC1 endeavours towards sustainability, and focussing on user demand, scientific excellence and productivity, EBiSC2 will deploy a business strategy for a sustainable, non-for-profit bank providing access to disease-relevant and quality-controlled iPSCs, along with comprehensive data and freedom to operate for academic and commercial use. To meet evolving requirements from industry and academia, the cell catalogue will be constantly enriched through on-demand generation of new iPSC lines, including gene-edited lines and isogenic controls, iPSC-derived and progenitor cells. EBiSC2 will distribute cell lines and develop a range of additional cell services (incl. screening panels of disease-relevant iPSC and control lines in ready-to-use-formats) to extend its offer, while reducing operational costs through state-of-the-art upscaling and automation enabling bulk production of standardised high-quality cells. Proof-of-concept studies performed jointly by academia and industry will demonstrate the reliability and robustness of the lines for disease modelling and screening and enrich the EBiSC2 catalogue with extensive data. To bundle resources, EBiSC2 focuses on collaboration with iPSC programmes and aims to serve as central hub for EU-funded projects to bank their iPSC lines, and thus, enable long-term access by the research community to the results of European investments.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EBISC2" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EBISC2" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More